Clonal hematopoiesis of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. Neutralization of the cytokine IL-1β (as in the CANTOS clinical trial) resulted in a greater reduction in adverse cardiovascular events in patients with CHIP than the reduction in molecularly unstratified patients. New research reveals that some of the cardiovascular benefits of anti-IL-1β therapy in patients with CHIP might be delivered by an improvement in plaque stability via increased fibroblast-like cells.
References
Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).
Fuster, J. J. et al. Science 355, 842–847 (2017).
Fidler, T. P. et al. Nature 592, 296–301 (2021).
Ridker, P. M. et al. N. Engl. J. Med. 377, 1119–1131 (2017).
Svensson, E. C. et al. JAMA Cardiol. 7, 521–528 (2022).
Fidler, T. P. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00405-9 (2023).
Gomez, D. et al. Nat. Med. 24, 1418–1429 (2018).
Li, J. et al. Blood 123, 3139–3151 (2014).
Raber, L. et al. J. Am. Med. Assoc. 327, 1771–1781 (2022).
Everett, B. M. et al. Circulation 139, 1289–1299 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
X.L. is an inventor on the UK patent ‘Treatment of Inflammatory Diseases’ (application no. 2313514.8). M.C.H.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Li, X., Clarke, M.C.H. Expansion of fibroblast-like cells may explain the CANTOS meta-analysis findings for patients with clonal hematopoiesis. Nat Cardiovasc Res 3, 23–25 (2024). https://doi.org/10.1038/s44161-023-00409-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-023-00409-5
- Springer Nature Limited